INTRODUCTION
Immunosuppression plays an integral role in solid organ transplant (SOT) recipients because it increases graft survival; however, there are unintended consequences, such as infectious complications. One strategy aimed at assessing the functionality of the immune system consists of non-pathogen-specific immune monitoring, consisting of serum immunoglobulins, serum complement factors, peripheral blood lymphocyte subpopulations, soluble CD30, and iATP in CD4 1 T cells. 1 Ideally, these would help to demonstrate one aspect of the overall "net state of immunosuppression." The "net state of immunosuppression" comprises all factors that may contribute to the risk of infection; this includes preexisting immune deficits, colonization with antimicrobial-resistant pathogens, immunosuppressive agents, acquired immunodeficiency, prior antimicrobial therapies, mucocutaneous barrier integrity, fluid collections, neutropenia, lymphopenia, and viral coinfections. 2 Disclosure Statement: A. Guenette has no relationships with a commercial company that has a direct financial interest in subject matter or materials discussed in article or with a company making a competing product. S. Husain has received grants from Astellas, Pfizer, and Merck. a Division of Infectious Disease, University Health Network, University of Toronto, 585 University Avenue, 11 PMB 138, Toronto, Ontario M5G 2N2, Canada;
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Vaccinations, surgical prophylaxis, universal prophylaxis, preemptive or presymptomatic therapy, targeted prophylaxis, and education avoidance are preventative strategies that have been implemented in SOT recipients. Trimethoprim/sulfamethoxazole prophylaxis is given in most institutions for 3 months to a lifetime to prevent Pneumocystis pneumonia along with Toxoplasma gondii, Cyclospora cayetanensis, and many Nocardia and Listeria species. Antiviral prophylaxis along with nucleic acid-based assays to prevent cytomegalovirus (CMV) and other herpesvirus infections has also transformed posttransplant care. 2 Infections in SOT recipients reflect the net balance between the recipient's epidemiologic exposures and immunosuppression. 2 Alterations to the balance can be seen with antimicrobial prophylaxis, immunosuppression, and improved graft survival. 2 This balance is also affected during a period of graft rejection or intensification of immunosuppression (Fig. 1) . 2 In this article, the authors review infectious syndromes encountered in intensive care units among SOT recipients.
BLOODSTREAM INFECTIONS/SEPSIS
Bloodstream infections (BSIs) are associated with poor outcomes along with being the leading cause of mortality and morbidity in SOT. [3] [4] [5] Mortality as high as 24% 4,6,7 has been described, and in fact, once septic shock develops, mortality can reach 50%, 4, 8 although Kalil and colleagues 9 demonstrated that there may be a decrease in mortality of transplant patients compared with nontransplant patients. It is thought that SOT recipients do not necessarily clinically behave in the same manner due to underlying immunosuppression, and in fact, tend to present with organ failure and thrombocytopenia during sepsis. 10 Universal risk factors for sepsis, regardless of transplanted organ, are CMV serology mismatch, particularly positive donor to negative recipient, CMV disease, which inherently demonstrates an immunomodulatory effect predisposing recipients to higher rates of bacterial and fungal sepsis, prolonged duration of graft cold ischemia, prolonged duration of surgical transplantation procedure, and requirement of large amounts of blood transfusion. 10, 11 Management should consist of rapid initiation of intravenous antibiotics, rapid diagnosis, source control, aggressive search for pathologic condition that mimics severe sepsis, and reduction in immunosuppressive drugs. 10 Nosocomial BSIs are associated with an even increased risk of septic shock and failure of cure when compared with other BSIs in SOT patients. [3] [4] [5] 8, 12 Grampositive bacteria are the most frequent source of BSIs and are likely to be associated with intravascular catheters, especially in the nosocomial setting.
3,4 However, with kidney transplant recipients (KTRs), gram-negative bacteria likely related to urinary tract infections (UTIs) are the primary source, regardless of the time period.
The overall incidence of multidrug-resistant organisms (MDRO) is increasing. MDRO gram-negative organisms accounted for about 14% of isolates. 4 Fluconazoleresistant Candida spp accounted for up to 46% of cases of candidemia according to Moreno and colleagues. 4, 13 Vancomycin-resistant enterococci (VRE) have become an emerging pathogen with studies documenting an incidence of up to 20.5% of nosocomial Enterococcal spp BSIs consistent with VRE. These findings along with previous microbiological history and local antibiotic resistance patterns should be considered when determining empiric antimicrobial therapy.
Overall, there are limited studies on infective endocarditis (IE) in sold organ transplant recipients. The incidence of IE in a single center was 1%, with an estimated 171-fold higher incidence as compared with the general population, 14 with an overall mortality up to 57%. 15 There are limited data on the mode of infection and predisposing factors in SOT recipients. Underlying structural abnormalities may not appear to be a risk factor for IE as compared with the general population. 14, 15 According to Paterson and colleagues, 15 50% of infections were due to Aspergillus fumigatus or Staphylococcus aureus, and 4% were due to viridans streptococci, which is in contrast to the general population. A combination of antibiotic therapy as described in Infectious Diseases Society of America (IDSA) Guidelines, Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications and surgical management, if warranted, is the current management.
Empiric management of suspected sepsis/BSI should include gram-positive coverage, in the presence of intravascular catheters, and broad gram-negative coverage. The choice of the antibiotic is dependent on the local epidemiology and previous microbiological data. Empiric Candida or antifungal coverage is not required, because the early initiation of antifungal has not been shown to improve the outcome in randomized controlled trials of mostly immunocompetent patients. 16, 17 
RESPIRATORY TRACT INFECTIONS
Bacterial pneumonia is the most common cause of lower respiratory tract infections. [18] [19] [20] [21] [22] [23] [24] According to Giannella and colleagues, 25 community-acquired pneumonia (CAP) was found in 40.7% and hospital-acquired pneumonia (HAP) was found in 59.3% of SOT recipients treated for pneumonia. In lung transplant recipients, bacterial pneumonia or bronchitis accounts for 32% to 63% of all infections with the incidence of bacterial pneumonia peaking in the first 4 to 8 postoperative weeks and then declines by the fourth month. Perioperative antibiotics, which are focused on preoperative cultures from the recipient and donor, reduce the incidence of early bacterial pneumonia to less than 10%. 20, 21 Regarding cardiac, hepatic, and renal transplants, the incidence of early bacterial pneumonia is 15%, 9%, and 4% to 6%, respectively, [18] [19] [20] 26, 27 with a mortality of 21% to 35% in liver and kidney transplant recipients. However, mortality between nosocomial and community-acquired infection was extreme at 58% compared with 8% [20] [21] [22] with mechanical ventilation and nosocomial infections at a higher increased risk for death. 18, [20] [21] [22] 24 In the initial perioperative
Infectious Complications
period, nosocomial pathogens, such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella species, Acinetobacter species, and S aureus, including methicillinresistant S aureus (MRSA), should be considered in the immediate perioperative period; however, prolonged mechanical ventilation following transplant increases the risk for nosocomial pneumonia. [20] [21] [22] Community-acquired pathogens, such as Haemophilus influenzae, Streptococcus pneumoniae, and Legionella species, may be seen. With the implementation of trimethoprim-sulfamethoxazole prophylaxis, the incidence of Nocardia pneumonia has decreased; however, it is still reported. 20, 28 Empiric treatment should take into consideration previous microbiological data, local epidemiology, and recent clinical history with regards to empiric antibiotic coverage.
Respiratory viral infections are a significant cause of mortality and morbidity among transplant recipients, including influenza, respiratory syncytial virus, parainfluenza virus, rhinovirus, human metapneumovirus, and coronavirus. The seasonal pattern usually follows that of the general public. [29] [30] [31] Disease can consist of mild congestion and rhinorrhea to more severe tracheobronchitis, bronchiolitis, and pneumonia. Clinical manifestation can range from mild or atypical symptoms, including absence of fever, with lung transplant recipients presenting with a more severe clinical course and complications. 29, 32 Viral shedding is usually prolonged and seen even with the use of antivirals. 29, 32 Transplant recipients are at higher risk of infectious complications, including fungal and bacterial pneumonia. Respiratory viral infections appear to be a risk factor for both acute and chronic rejection, especially in lung transplant recipients. 29, [33] [34] [35] [36] Diagnostic workup should consist of a nasopharyngeal swab, wash, or aspirate. If upper tract samples fail to document the cause or if there is clinical or radiological evidence of lower tract involvement, bronchoalveolar lavage (BAL) should be considered. Polymerase chain reaction (PCR)-based assays are commercially available with many centers adopting them because they are the most preferred mode of testing given the high sensitivity along with most allowing for simultaneously detecting a broad range of respiratory pathogens from a single sample. Treatment, as is outlined in Fig. 2 , includes supportive care and reduction in immunosuppression.
Adenovirus is a nonenveloped, lytic double-stranded DNA virus that can be acquired de novo, through reactivation of a latent infection of the recipient, or from transplant organ. Transmission occurs by respiratory route, person-to-person contact, or fecal-oral route. The true incidence among SOT recipients is unknown, with most infections occurring within the first year after transplantation. 37 Clinical manifestations can vary; however, when affecting lung transplant recipients, it can produce a range of clinical manifestations, including acute flulike illness, diffuse alveolar damage, or necrotizing pneumonia along with chronic changes, such as bronchiolitis obliterans, interstitial fibrosis, or bronchiectasis. [38] [39] [40] [41] Viral culture, direct antigen detection, molecular methods, and histopathology are available for diagnosis with histopathologic evaluation, as the gold standard for the diagnosis of invasive disease. Rapid antigen detection kits, in particular, immunofluorescence assays when processing respiratory specimens, are commercially available, which yield rapid and specific results. PCR, qualitative and quantitative, has emerged as a widely used tool for detection because it is highly sensitive and rapid. Recovery of adenovirus from respiratory samples does not necessarily confirm disease because patients can shed asymptomatically for a prolonged period of time; therefore, it is essential to correlate with clinical findings along with detection of virus from other sites and histopathological findings. Cidofovir has the best evidence to support its use in the treatment of adenoviral infections. Brincidofovir, the lipid conjugate of cidofovir, has also demonstrated in vitro susceptibility and appears to be promising in vivo with regards to SOT recipients; however, further studies are warranted. 42 CMV is a major pathogen in SOT recipients, with the ability to cause end-organ disease. The immunomodulatory effects of CMV, impaired T-cell and phagocytic function, and cytokine dysregulation can lead to opportunistic infections, rejection, graft loss, and reduced survival. 43, 44 The transplant recipients who are at highest risk are seronegative recipients of seropositive organ, D1/RÀ, because they have no preexisting immunity, and seropositive recipients, DÀ/R1, are at intermediate risk. There is little difference between D1/R1 and DÀ/RÀ groups, with potentially worse outcomes in D1/R1 (Fig. 3) . 43 Clinical presentation consists of dyspnea, fever, and malaise with the identification of characteristic CMV cells in lung tissue. Radiographic changes are nonspecific and include diffuse haziness, focal haziness, focal lobar consolidation, and no change. 20 Diagnosis is made via cell culture viral isolation; however, this can be time consuming. Therefore, the detection of CMV DNA by PCR in the peripheral blood leukocytes, providing a sensitivity of 92% and specificity of 76% for CMV pneumonitis, along with the BAL CMV DNA PCR, is an alternative means to diagnosis. 20, 45 However, with regards to the BAL findings, it would be imperative to differentiate between infections versus shedding; hence, the concomitant peripheral blood leukocyte PCR along with the clinical picture is necessary to help determine the diagnosis. Treatment consists of ganciclovir or the oral alternative, valganciclovir. Foscarnet and cidofovir are alternative options; however, they are primarily reserved when there is a concern for resistance or documented resistance because their side-effect Fig. 3 . CMV serostatus and the risk of complications.
profiles are less desirable. 20 CMV immunoglobulin in conjunction with treatment offers limited efficacy. 43 Maribavir, brincidofovir, and letermovir are novel agents that may provide alternative options for treatment; however, further studies are warranted.
Candida is a frequent colonizer of lung transplant recipients, but less than 10% of patients colonized develop invasive disease. 20, 46 Bronchial anastomotic infections may occur early in the postoperative setting, which can lead to anastomotic failure, parenchymal lung infection, and mediastinitis. [47] [48] [49] [50] [51] [52] Artificial bronchial stents can serve as a potential site for infection. 47, 48 Candida tracheobronchitis is based on visual inspection and histologic confirmation along with positive cultures from an appropriate specimen. 47 Aspergillus species, a saprophytic organism, has higher rates of mortality, up to 54%, and an incidence of 3% in lung, 2.4% in heart, 2% in liver, and 0.2% in kidney transplant recipients. 47 Infection may be due to reactivation or de novo infection following inhalation of the mold. Renal failure, hemodialysis, repeated bacterial infections, leukopenia, CMV disease, high levels of immunosuppression, retransplantation, chronic exposure of the transplanted lung to the environment, and abnormal anatomic and physiologic function of the transplanted and, if still present, the native lung, airway ischemia, hypogammaglobulinemia, cystic fibrosis, and bronchial stent are all risk factors for invasive aspergillosis. 47, [53] [54] [55] [56] In lung transplant recipients, 20% to 40% are colonized with Aspergillus with complicated infections affecting up to 13% of all patients. 20, [57] [58] [59] [60] Colonization can also lead to bronchiolitis obliterans syndrome after lung transplantation. 47, 61 Clinical manifestations can range from asymptomatic colonization to tracheobronchitis, invasive pulmonary aspergillosis, empyema, and disseminated disease, 47, 62 with symptoms including purulent sputum, fever, malaise, respiratory distress, and hemoptysis. 20, 63 Aspergillus tracheobronchitis can cause airway obstruction, ulcerations, and pseudomembrane formation. 47 Nonaspergillus mycelial fungi are also increasing with frequency, as high as 30%, and an overall mortality of 55% 20, 64 ; however, zygomycosis (rhizopus and mucor species) and non-aspergillus hyalohyphomycosis (scedosporium apiospermum and fusarium species) have an even higher mortality of up to 100%. 20 Endemic fungi, Coccidioides immitis, Histoplasma capsulatum, Blastomyces dermatitidis, and cryptcoccus are additional pathogens that may need to be considered.
Radiological findings may demonstrate nodules, cavitary lesions, focal consolidation or patchy densities, wedge-shaped pleural-based lesions, air-filled bronchi with an intraluminal lesion, "air crescent" sign, and halo of decreased density. Tissue invasion by fungal organisms is the gold standard for diagnosis of invasive fungal pneumonia. However, this may be difficult to obtain; therefore, International Society for Heart and Lung Transplantation developed guidelines, A 2010 Working Formulation for the Standardization of Definitions of Infections in Cardiothoracic Transplant Recipients, to assist in the diagnosis of not only fungal infections but also bacterial and viral infections. These definitions may also be applied to abdominal transplant recipients. Treatment is as follows in Fig. 4 ; however, be aware of drug-drug interactions with regards to immunosuppressive agents. It is important to note, however, that empiric management of mold infections in SOT recipients is seldom necessary. The optimal approach is to pursue the diagnostic workup aggressively and treat accordingly even in lung transplant recipients.
Pneumocystis jirovecii, T gondii, Mycobacterium tuberculosis, and nontuberculosis mycobacteria are other pathogens to also consider as possible causes of respiratory tract infections along with the other pathogens listed in Fig. 5 .
NEUROLOGIC INFECTIONS
Central nervous system (CNS) infections can account for approximately 5% to 10% of CNS lesions in transplant recipients. 20, 64 Routine prophylaxis aimed at opportunistic infections along with a more conservative approach regarding immunosuppression has led to noticeable trends in infections in transplant recipients. For example, routine administration of trimethoprim-sulfamethoxazole for P jirovecii has likely contributed to the reduction in infections owing to T gondii, Nocardia, and Listeria monocytogenes along with acyclovir and valganciclovir attributing to the likely decline in herpesviridaerelated infections. 65, 66 Clinical presentation will vary and may include fever, headache, meningismus, Kernig and Brudzinski signs, new-onset seizure, papilledema, altered sensorium, and/or focal neurologic deficits; however, because of their underlying immunosuppression, these may be subtle or absent. 65, 67 As listed in Fig. 6 , possible causes range from community-acquired organisms, donor-derived infections, reactivation, to opportunistic pathogens. Metastatic or direct lesions along with "pulmonary-brain" syndrome are also considerations in such organisms as Cryptococcus, Nocardia, Aspergillus, Zygomycetes, Strongyloides, and Toxoplasma; therefore, further investigations are warranted (eg, computed tomography of sinus and computed tomography of chest).
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Evaluation should include neuroimaging along with lumbar puncture as soon as possible if no contraindication exists. Cerebral spinal fluid examination should always include cell counts and differential, glucose, protein; routine smears; and cultures for bacteria, fungi, and mycobacteria. 65, 67 Additional specialized testing, such as viral PCR, antigen or antibody, and 16S ribosomal RNA, may be required depending on the clinical scenario. 65, 67 However, brain biopsy with appropriate staining may be the definitive diagnosis if findings are inconclusive. Empiric treatment should cover common bacterial and viral pathogens; however, additional agents may be needed depending on the epidemiologic history.
HEPATOBILIARY INFECTIONS
Cholangitis is a common infection after liver transplant, and in fact, is the most common infection more than 1 year after liver transplant. 68 Most cases occurred within 5 years and were associated with primary sclerosing cholangitis and Rouxen-Y anastomosis. 68 The most frequently identified bacteria are Enterococcus spp and E coli 68, 69 ; however, other gram-negative bacilli and anaerobes should also be considered. 68, 69 Bile leaks can occur in 2% to 25% of cases after liver transplantation, especially in living liver donor transplants. 70 Clinical presentation varies with extent of the leak; however, symptoms can include abdominal pain, fever, or any sign of peritonitis. However, because of underlying immunosuppression, they can also be asymptomatic. 70 In these cases, elevations in serum bilirubin, fluctuations in cyclosporine, or bilious ascites should raise suspicion for a bile leak. 70 Biliary strictures at the site of anastomosis can also present with fever, abdominal pain, but also jaundice and asymptomatic biochemical cholestasis. 70 Bilomas can represent an additional source of infection. 41, 70 Hepatic artery thrombosis, although more common in living donor liver transplants (LDLTs), is uncommon with deceased donor liver transplant (DDLT) with an overall incidence up to 9% and can lead to complications, including hepatic abscesses, necrosis, sepsis, and graft loss. 71 Vancomycin-resistant Enterococcus faecium (VREF) is of particular concern in liver transplant. Pretransplant colonization increases rates of intra-abdominal and BSIs after transplantation. 72, 73 In fact, hospital and intensive care unit stays are longer for patients with VREF versus vancomycin-sensitive E faecium infections. 72 Liver, pancreas, and intestinal recipients are at particular risk for fungal infections, most often caused by Candida species. 41, 74, 75 Regarding DDLT versus LDLT, there are variations with infectious complications. The rate of infection appears to be similar to DDLT; however, because of the more complex nature of the surgery, there are observable difference and specific concerns as detailed in Box 1.
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The clinical syndrome of hepatic dysfunction can range from mild elevated liver enzymes to hepatitis to fulminant hepatic failure. Hepatic dysfunction can present in any SOT recipient; however, of utmost concern would be liver transplant recipients. Causes can range from infectious to noninfectious with noninfectious causes primarily an issue with liver transplant recipients regarding postoperative complications, recurrence of primary disease, drug-induced complications, and rejection. 79 The infectious causes listed in Fig. 7 can range from donor-derived infections, postoperative complications, community-acquired organisms, reactivation, to opportunistic pathogens. Evaluation should include imaging (eg, ultrasound, computed tomography, or MRI) along with the appropriate infectious workup (eg, blood cultures, serum PCR, serology, antigen, and/or antibodies). If the diagnosis remains inconclusive, a liver biopsy may need to be pursued with appropriate staining obtained.
ENTEROCOLITIS
Diarrhea following transplantation is frequently observed and is estimated to occur in 22% to 52% of patients. [80] [81] [82] [83] [84] It can be associated with allograft loss and increased mortality. 80, 82, 85, 86 In fact, it results in 900,000 hospitalizations and 6000 deaths annually. 87, 88 The severity and cause of diarrhea can lead to hypovolemia and/or septic shock. Diarrhea is a recognized side effect of some immunosuppressive agents; however, infectious causes should be considered based on the clinical picture. Causes are detailed in Fig. 8 . Evaluation should include stool culture, ova and parasite and giardia antigen along with appropriate PCR, antigen testing, and/or special staining. Imaging may include a computed tomography to evaluate for bowel wall edema along with colonic wall thickening and dilation. 87 Esophagogastroduodenoscopy (EGD) and/or colonoscopy along with biopsy may also be warranted. CMV colitis is diagnosed via histopathology obtained during a biopsy. Serum PCR can be low to undetectable in this setting. If there is a clinical suspicion (eg, elevated serum PCR along with diarrhea, however the patient is unable to undergo colonoscopy), this may warrant empiric treatment.
Clostridium difficile infection (CDI) is among the most common health careassociated pathogen and is the most common cause of nosocomial infectious diarrhea. 89 The highest incidence of CDI in SOT occurs within the first 3 months following the transplant and is likely related to frequent exposure to antimicrobials, health care settings, and immunosuppressants. 89 Proton pump inhibitors (PPIs) are known to be a risk for CDI and may still be used in the setting of mechanical ventilation, versus H2 blockers. 90 Hospitalized patients who use PPIs are twice as likely to develop CDI. 89, 91 Fulminant colitis develops in up to 13% of SOT recipients with CDI. 89, 92 Relapsing disease is common, and protracted courses of therapy are often essential. 74, 93, 94 IDSA and Society for Healthcare Epidemiology of America recently updated the Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children for 2017, and although this is for immunocompetent patients, these guidelines can be applied to SOT recipients because there have been limited studies into the treatment of CDI in SOT patients.
GENITOURINARY INFECTIONS
The most common infectious complication in SOT is UTI, accounting for 45% to 72% of all infections, and 30% of all hospitalizations for sepsis in KTRs. 19, [95] [96] [97] [98] [99] Most UTI are seen within the first 6 months after transplant; however, it can occur any time after transplantation. 96, 100, 101 Empirical treatment is imperative, as it has been demonstrated that inappropriate antibiotic therapy is associated with an increase in mortality. 100, 102, 103 To guide empirical therapy, local epidemiologic data, patient's microbiological history, and prior antibiotic use need to be taken into account. 95, 100 The most frequent organisms causing UTIs are gram-negative bacilli 100, 104 ; however, when a urinary catheter is involved, Enterococci and S aureus should also be considered. The duration of treatment varies from 7-21 days depending on the clinical syndrome. Recurrent UTI, defined as 3 or more episodes of symptomatic UTIs over a 12-month period or 2 in the previous 6 months, should prompt further investigation regarding anatomic and functional abnormalities along with behavioral modifications (eg, postcoital voiding) and may need a prolonged course of antibiotics, possibly 4 to 6 weeks. 95, 100, 101 Asymptomatic bacteriuria should only be treated during the early postoperative period and up to 1 month after transplant in renal transplant patients. 100 The data on UTI related to Candida spp in SOT are limited and mostly include KTR. In KTR, Candida spp are the most frequently isolated fungal cause of UTI. Unfortunately, there are no clinical trials in the management of Candida UTI in SOT. 100 Candiduria is frequent, occurring in up to 11% of KTR; however, it is mostly asymptomatic. 95 Asymptomatic candiduria is usually treated as there is concern regarding the allograft and potential for complications regarding the upper urinary tract; however, it should only be treated if the patient is neutropenic, or undergoing a urologic procedure. 95 ,100 Candiduria should be classified based on risk factors for disseminated candidiasis. Urinary catheters should be removed or exchanged, and candiduria should be confirmed with a second, clean voided urine culture. Disseminated candidiasis may be considered if clinical manifestations are consistent (eg, positive blood cultures, a second urine culture after removal or replacement of the urinary catheter, funduscopic examination, cultures from any other significant site, and kidney imaging). Persistent candiduria along with Infectious Complications no indwelling catheters should prompt imaging of the kidneys and collecting system to exclude renal abscess, fungus balls, or other urologic abnormalities. Treatment options can range from fluconazole treatment of choice, to echinocandins, amphotericin B, and flucytosine depending on the clinical situation and organism sensitivities with durations from at least 14 days for UTI to 2 to 4 weeks for pyelonephritis (Box 2).
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SUMMARY
SOT recipients are a complex group of patients with diverse causes given the underlying immunosuppression. As with all infectious processes, rapid identification of the 
Respiratory tract infections
Always consider previous microbiological data and local epidemiology with regards to empiric antibiotics CAP should include empiric coverage for atypicals along with community-associated organisms HAP and VAP should include broad gram-positive coverage, especially MRSA, along with broad gram-negative coverage, including ESBLs and CREs if warranted Influenza is the only virus with approved treatment, oseltamavir; therefore, this should be started empirically if there is a concern Antifungals should not be started empirically, even in lung transplant recipients; however, fungal infections should be worked up thoroughly pathogen, source control, and adjustment of immunosuppression is the hallmark of treatment. There is a summary of the management of infections in SOT recipients included in Box 3.
CNS infections
Empiric therapy should consist of ceftriaxone and vancomycin AE acyclovir
Hepatobiliary and gastrointestinal infections
Always consider previous microbiological data and local epidemiology with regards to empiric antibiotics If VRE positive, will need to consider coverage using high-dose daptomycin or linezolid along with broad gram-negative coverage, including ESBLs and CREs, if warranted Regarding C difficile infections, oral vancomycin should be initiated empirically, if suspected, as first-line therapy
Genitourinary infections
Always consider previous microbiological data along with local epidemiology with regards to empiric antibiotic decisions Asymptomatic bacteriuria should only be treated in renal transplant patients during the first month posttransplantation Antimicrobials should be tailored to the causative agent, with durations that generally range from 7 to 21 days depending on the clinical context Fluconazole is the treatment of choice for cystitis and pyelonephritis if Candida is the causative organism Abbreviations: CRE, carbapenem-resistant enterobacteriaceae; ESBL, extended spectrum betalactamase inhibitors; VAP, ventilator-associated pneumonia.
